Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
RecruitingThe goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests
PhasePhase 3
TypeInterventional
Age18 Years – 80 Years
WherePhoenix, Arizona, United States + 55 more
SponsorPrilenia
▾Tap for detailsClick for full details — eligibility, all locations, contacts The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases. ASSESS protocol is specific for symptomatic ALS and control participants. This protocol includes both on-site and off-site(remote) participants. The participants will be followed for 24 months (2 years), and will include collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once a month. Participants who are coming into clinic may also provide optional Cerebrospinal Fluid (CSF) samples.
Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 36 more
SponsorSt. Joseph's Hospital and Medical Center, Phoenix
▾Tap for detailsClick for full details — eligibility, all locations, contacts Healey ALS MyMatch Common Screening Protocol
RecruitingThe Healey ALS MyMatch Common Screening Protocol (MCSP) is an observational study. The main goal of the study is to help connect adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them. People who complete an MCSP Screening Visit will undergo: * clinical assessments * laboratory testing * biomarker analyses The above will be used to determine preliminary eligibility for enrolling ALS MyMatch trials. In addition to helping connect people to a Healey ALS MyMatch interventional clinical trial, the information will also be used to characterize clinical, genetic, and biofluid biomarker profiles. These profiles will help to match the right people to the right trials and evaluate the frequency of ALS-associated gene variants. Blood samples and DNA will also be stored for future ALS and biomarker research.
Phase—
TypeObservational
Age18 Years
WhereDavie, Florida, United States + 3 more
SponsorMassachusetts General Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684 · Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
RecruitingARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 25 more
SponsorMayo Clinic
▾Tap for detailsClick for full details — eligibility, all locations, contacts Clinical Outcome Assessment for AT & BCI
RecruitingMany individuals with severe motor impairments rely on Assistive Technologies (ATs) or Brain-Computer Interfaces (BCIs) to interact with digital devices such as their computers. Clinicians and researchers currently lack a common framework to objectively quantify how much a given AT or BCI improves real-world function or to compare across tools. This project seeks to address this gap by developing a standardized method to objectively assess or compare the functional benefit of these tools on digital independence, i.e., the ability to independently operate computers, phones, and other digital systems, by creating a unique Digital Assessment Interface (DAI). This assessment will be a simulation of online and digital activities that prior work has determined is important to functional daily living in the digital domain. Participants will complete this assessment with various ATs and BCIs, and these scores will be used to create an index, which will be comprised of performance outcomes, clinician-reported outcomes, and patient-reported outcomes. The tool aims to quantify and compare digital task performance across devices and user populations. The primary objective of this study is to develop an index. The index will quantify functional performance of individuals using various ATs and BCIs. The secondary objectives are to extensively evaluate the psychometric properties of the index, such as the validity, responsiveness, reliability, and floor/ceiling effects both globally and across different devices and impairment levels, ensuring that it can reliably measure the impact of an AT or BCI on a user's ability to independently operate digital systems; and to characterize the familiarization and use of specific BCI and AT systems with reference to a normative healthy control population.
PhaseNA
TypeInterventional
Age18 Years
WhereChicago, Illinois, United States
SponsorShirley Ryan AbilityLab
▾Tap for detailsClick for full details — eligibility, all locations, contacts Analysis of Human ALS Tissues and Registry of ALS Patients
RecruitingAmyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a need to identify both reliable markers of disease progression and effective treatments. The goal of this research is to bring a greater understanding of ALS patients closer to the research studies that can lead to new hypotheses and approaches.
Phase—
TypeObservational
Age18 Years – 90 Years
WhereChicago, Illinois, United States
SponsorUniversity of Illinois Chicago
▾Tap for detailsClick for full details — eligibility, all locations, contacts ALS/MND Natural History Study Data Repository
NCT05966038 ·
ALS, PLS, MND (Motor Neurone DIsease)
RecruitingThis is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND). All people living with ALS or other MNDs who attend clinics at the Study hospitals (sites) are offered to participate in the Study. The Sites collect so-called Baseline information including demographics, disease history and diagnosis, family history, etc. At each visit, the Sites also collect multiple disease-specific outcome measures and events. The information is captured in NeuroBANK, a patient-centric clinical research platform. The Sites have an option to choose to collect data into 20+ additional forms capturing biomarkers and outcome measures. Captured data after its curation are anonymized (all personal identifiers and dates are being removed), and the anonymized dataset is shared with medical researchers via a non-exclusive revocable license. Funding Source - Biogen, Inc.; Mitsubishi Tanabe Pharma America; FDA OOPD.
Phase—
TypeObservational
Age18 Years – 90 Years
WhereLoma Linda, California, United States + 17 more
SponsorMassachusetts General Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
NCT05137665 ·
Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder
RecruitingThe goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.
Phase—
TypeObservational
Age18 Years
WherePhoenix, Arizona, United States + 11 more
SponsorTarget ALS Foundation, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 · Adjustment Disorder
RecruitingThe purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereBirmingham, Alabama, United States + 32 more
SponsorReunion Neuroscience Inc
▾Tap for detailsClick for full details — eligibility, all locations, contacts